, Volume 20, Issue 11, pp 775–784 | Cite as

Conjoint Analysis of a New Chemotherapy

Willingness to Pay and Preference for the Features of Raltitrexed versus Standard Therapy in Advanced Colorectal Cancer
  • Mike AristidesEmail author
  • Jack Chen
  • Mark Schulz
  • Eve Williamson
  • Stephen Clarke
  • Kaye Grant
Original Research Article


Objective: To estimate the willingness to pay for a new chemotherapy, raltitrexed (Tomudex™1) over conventional therapy with fluorouracil plus leucovorin (FU-LV) from the perspective of patients with advanced colorectal cancer. The study was part of the product’s reimbursement application in Australia.

Design and Methods: The key differences relevant to patients between the two therapies, frequency of administration and severity of mouth ulceration, were used to develop a self-administered questionnaire. A relatively new technique to healthcare, that of conjoint analysis (CA), was used to estimate willingness to pay and strength of preference. A discrete choice CA was used. Analysis was via a logit model with adjustment for the cluster effect (or intra-patient correlation).

Study participants: Oncology nurses served as proxies for patients with advanced colorectal cancer.

Results: The participation rate was 87% (62/71) with questionnaires from 56 respondents eligible for analysis. The CA method generated a mean incremental willingness to pay of 745 Australian dollars ($A; $US507) per cycle of chemotherapy, comprising $A550 ($US374) and $A195 ($US133) for the toxicity and administration improvements, respectively (1998 values). Both features were related to preference with independent odds of 6.87 and 1.98, respectively, however only the toxicity attribute was a significantly related to preference. Subscription to private health insurance was the only significant demographic predictor identified, however, the homogeneous income structure of the respondents seems likely to have masked any significant income effect.

Conclusions: This study highlights the advantages of using CA in healthcare, where new therapies or treatments are often composed of a number of attributes. The CA allows both strength of preference and willingness to pay for individual treatment attributes to be estimated and can be used to assign statistical significance to these parameters.


Logit Model Utility Score Attribute Level Baseline Scenario Conjoint Analysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was conducted with the financial assistance of AstraZeneca, Australia.


  1. 1.
    Donaldson C. Willingness to pay for publicly provided goods: a possible measure of benefit. J Health Econ 1990; 9: 103–18PubMedCrossRefGoogle Scholar
  2. 2.
    Coley CM, Li Y, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med 1996; 156: 1565–71PubMedCrossRefGoogle Scholar
  3. 3.
    Granberg M, Wiklan M, Nilsson L, et al. Couples willingness to pay for IVF/ET. Acta Obstet Gynecol Scand 1995; 74: 199–202PubMedCrossRefGoogle Scholar
  4. 4.
    Hudmon SK, Stoltzfus C, Chamberlain RM, et al. Participant’s perceptions of a phase I colon cancer chemoprevention trial. Control Clin Trials 1996; 17: 494–508PubMedCrossRefGoogle Scholar
  5. 5.
    Morrison GC, Gyldmark M. Appraising the use of contingent valuation. Health Econ 1993; 1: 233–43CrossRefGoogle Scholar
  6. 6.
    O’Brien B, Novosel S, Torrance G, et al. Assessing the economic value of a new antidepressant: a willingness-to-pay approach. Pharmacoeconomics 1995; 8 (1): 34–45PubMedCrossRefGoogle Scholar
  7. 7.
    Olsen JA, Donaldson C. Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. Soc Sci Med 1997; 46: 1–12CrossRefGoogle Scholar
  8. 8.
    Ritchie LD. A willingness-to-pay analysis: comparison of the patient preference for topical flurbiprofen local action transcutaneous patches and piroxicam gel. Br J Med Econ 1996; 10: 291–302Google Scholar
  9. 9.
    Cattin P, Wittink D. Commercial use of conjoint analysis: a survey. J Marketing 1982; 46: 44–53CrossRefGoogle Scholar
  10. 10.
    Farrar S, Ryan M. Response-ordering effects: a methodological issue in conjoint analysis. Health Econ 1999; 8: 75–9PubMedCrossRefGoogle Scholar
  11. 11.
    Ryan M. Economics and the patient’s utility function: an application to assisted reproductive techniques [dissertation]. Aberdeen: University of Aberdeen, 1999Google Scholar
  12. 12.
    Ryan M. Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation. Soc Sci Med 1999; 48: 535–46PubMedCrossRefGoogle Scholar
  13. 13.
    Ryan M, Hughes J. Using conjoint analysis to value surgical versus medical management of miscarriage. Health Economics Research Unit Discussion Paper No. 06/95. Aberdeen: University of Aberdeen, 1995Google Scholar
  14. 14.
    Ryan M, McIntosh E, Shackley P. Methodological issues in the application of conjoint analysis in health care. Health Econ 1998; 7: 373–8PubMedCrossRefGoogle Scholar
  15. 15.
    Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000; 320 (7248): 1530–3PubMedCrossRefGoogle Scholar
  16. 16.
    Aristides M, Mitchell A, Henry D. Economic evaluation and the subsidisation of pharmaceuticals. In: Davis P, editor. Contested ground: new directions in drug regulatory policy. New York (NY): Oxford University Press, 1996Google Scholar
  17. 17.
    O’Brien BJ, Goeree R, Gafni A, et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care 1998; 36: 370–84PubMedCrossRefGoogle Scholar
  18. 18.
    Cunningham D, Zalcberg JR, Rath U, et al. Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A: 1945–54PubMedCrossRefGoogle Scholar
  19. 19.
    Ryan M, Hughes J. Using conjoint analysis to assess women’s preferences for miscarriage management. Health Econ 1995; 6: 261–73CrossRefGoogle Scholar
  20. 20.
    Greene WH. Econometric analysis. 3rd ed. New York (NY): Prentice-Hall International, 1997Google Scholar
  21. 21.
    White H. A heteroscedasticity-consistent covariance matrix estimator and a direct test for heteroscedasticity. Econometrica 1980; 48: 819–930Google Scholar
  22. 22.
    White H. Maximum likelihood estimation of misspecified models. Econometrica 1982; 50: 1–25CrossRefGoogle Scholar
  23. 23.
    Binder DA. On the variances of asymptotically normal estimators from complex surveys. Int Stat Rev 1983; 51: 279–92CrossRefGoogle Scholar
  24. 24.
    Kish L, Frankel MR. Inference from complex samples. J Roy Stat Soc B 1974; 36: 1–37Google Scholar
  25. 25.
    Bryan S, Buxton M, Sheldon R, et al. Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. Health Econ 1998; 7: 595–603PubMedCrossRefGoogle Scholar
  26. 26.
    Gujarati P. Basic econometrics. 2nd ed. New York (NY): McGraw-Hill Book Company, 1988Google Scholar
  27. 27.
    Magat WA, Viscusi WK, Huber J. Paired comparison and contingent valuation approaches to morbidity risk valuation. J Environ Econ Manag 1988; 15: 395–411CrossRefGoogle Scholar
  28. 28.
    Propper C. Contingent valuation of time spent on NHS waiting lists. Econ J 1991; 100: 193–9CrossRefGoogle Scholar
  29. 29.
    Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomised, multicentre trial of raltitrexed vs fluorouracil plus high dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 2943–52PubMedGoogle Scholar
  30. 30.
    StataCorp. Stata statistical software: release 6.0. College Station (TX): Stata Corporation, 1999Google Scholar
  31. 31.
    Drummond M, Aristides M. The Australian cost-effectiveness guidelines: an update. In: Towse A, editor. Guidelines for the economic evaluation of pharmaceuticals: can the UK learn from Australia and Canada? London: Office of Health Economics, 1998Google Scholar
  32. 32.
    Henry DA. Economic analysis as an aid to subsidisation: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics 1992; 1 (1): 54–67PubMedCrossRefGoogle Scholar
  33. 33.
    Davey P, Grainger D, MacMillan J, et al. Economic evaluation of insulin lispro vs neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics 1998; 13 (3): 347–58PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Mike Aristides
    • 1
    Email author
  • Jack Chen
    • 1
  • Mark Schulz
    • 1
  • Eve Williamson
    • 2
  • Stephen Clarke
    • 3
  • Kaye Grant
    • 2
  1. 1.M-TAG Pty LtdSydneyAustralia
  2. 2.AstraZeneca PharmaceuticalsSydneyAustralia
  3. 3.Royal Prince Alfred HospitalSydneyAustralia

Personalised recommendations